T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
- Resource Type
- article
- Source
- HemaSphere, Vol 6, Pp 46-47 (2022)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 - Language
- English
- ISSN
- 2572-9241